Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START‐Laboratory Register

Comparison of five specific assays for determination of dabigatran plasma concentrations in... INTRODUCTIONThe direct thrombin inhibitor dabigatran has been the first direct oral anticoagulant (DOAC) approved for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and for prevention or treatment of venous thromboembolism. Although dabigatran was developed for fixed‐dose administration in patients with standard conditions without the need of routine laboratory monitoring and dose adjustment, there is now the widespread awareness that some clinical situations, such as adverse (thrombotic/hemorrhagic) events or emergency invasive procedures and others, might require the measurement of the drug plasma levels.The global coagulation test activated partial thromboplastin time (aPTT) was initially indicated as the method to measure the degree of anticoagulation in patients treated with dabigatran due to its wide availability and low cost. However, recent studies showed that aPTT has a low sensitivity to dabigatran levels and different responsiveness depending on commercial reagents. Furthermore, normal results are not always associated with the absence or minimal residual concentration of the drug. Over the last years, several manufacturers developed specific functional tests for dabigatran plasma levels assessment, including thrombin‐based clotting assays and ecarin clotting time or chromogenic assays. These methods showed good agreement with liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) that is considered as the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Laboratory Hematology Wiley

Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START‐Laboratory Register

Loading next page...
 
/lp/wiley/comparison-of-five-specific-assays-for-determination-of-dabigatran-qR8IIixq6F
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 John Wiley & Sons Ltd
ISSN
1751-5521
eISSN
1751-553X
D.O.I.
10.1111/ijlh.12772
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONThe direct thrombin inhibitor dabigatran has been the first direct oral anticoagulant (DOAC) approved for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and for prevention or treatment of venous thromboembolism. Although dabigatran was developed for fixed‐dose administration in patients with standard conditions without the need of routine laboratory monitoring and dose adjustment, there is now the widespread awareness that some clinical situations, such as adverse (thrombotic/hemorrhagic) events or emergency invasive procedures and others, might require the measurement of the drug plasma levels.The global coagulation test activated partial thromboplastin time (aPTT) was initially indicated as the method to measure the degree of anticoagulation in patients treated with dabigatran due to its wide availability and low cost. However, recent studies showed that aPTT has a low sensitivity to dabigatran levels and different responsiveness depending on commercial reagents. Furthermore, normal results are not always associated with the absence or minimal residual concentration of the drug. Over the last years, several manufacturers developed specific functional tests for dabigatran plasma levels assessment, including thrombin‐based clotting assays and ecarin clotting time or chromogenic assays. These methods showed good agreement with liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) that is considered as the

Journal

International Journal of Laboratory HematologyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off